Sana Aslam, DO
Neurology · Aurora, CONPI 1588074207
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Medtronic at 53.4% of the total. Reporting peaked in 2019 at $1,142 and has fallen 89.5% since, to $120 in 2025.
Across 30 payments — averaging $57.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$928
- Neurocrine Biosciences, Inc.$241
- Abbott$186
- Grifols USA, LLC$133
- Teva Pharmaceuticals USA, Inc.$120
- Boston Scientific$113
- plus $18 from 1 others
Across 97 payments — averaging $7143.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$537K
- Roche TCRC, Inc.$120K
- Boston Scientific$25K
- Biohaven Pharmaceutical Holding Company Ltd.$8K
- Biohaven Pharmaceuticals, Inc.$3K
What the payments were for
- Travel & lodging$65238%
- Food & beverage$1,01758%
- Education$704%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 13 | $928 |
| Neurocrine Biosciences, Inc. | 2 | $241 |
| Abbott | 7 | $186 |
| Grifols USA, LLC | 1 | $133 |
| Teva Pharmaceuticals USA, Inc. | 1 | $120 |
| Boston Scientific | 5 | $113 |
| Hoffmann-la Roche Limited | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTIVA$607
- Gamunex-C$133
- Austedo XR$120
- Infinity DBS Pulse Generators$100
How this compares
$1,739 in reported general payments places this provider in the 55th percentile of 334 neurology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RytaryCarbidopa/Levodopa | 37 | $75,035 |
| Rasagiline Mesylate | 26 | $7,958 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 100 | $3,719 |
| AmantadineAmantadine Hcl | 33 | $2,332 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 39 | $2,134 |
| Primidone | 23 | $507 |
| Gabapentin | 13 | $308 |
| Propranolol Hcl | 14 | $277 |
| Trihexyphenidyl Hcl | 12 | $245 |
| Clonazepam | 16 | $207 |
| Escitalopram Oxalate | 13 | $169 |
Paid to pharmacies, not to this prescriber.
Other neurology in Aurora
- Jeffrey BennettAurora$605K
- Enrique AlvarezAurora$407K
- Anna ShahAurora$157K
- Timothy VollmerAurora$136K
- Simon OhAurora$112K
- Amanda PiquetAurora$106K
- Brent MorelAurora$79K
- Drew KernAurora$68K
- Ondrea TimmermannAurora$33K
- Thomas RagoleAurora$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.